大成生化科技(00809.HK):旗下哈爾濱大成暫停生產
大成生化科技(00809.HK)公布,經考慮自2018年起亞洲爆發非洲豬瘟,導致市場景氣低迷,持續拖累玉米提煉行業表現,加上集團營運資金緊張,管理層已決定暫停間接全資附屬公司哈爾濱大成的生產。
哈爾濱大成主要從事玉米澱粉、蛋白粉、玉米油及其他玉米提煉產品的生產及銷售。哈爾濱大成的營業額及淨虧損分別佔集團截至6月底止六個月總營業額13%及淨虧損8.8%。
董事會認為,停產能減少經營現金流出及確保集團有充足資源投放於其他核心業務活動,故此舉符合公司及股東的整體最佳利益。預期停產不會對集團截至2019年12月31日止年度的財務狀況造成任何重大不利影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.